Oncovita secures US FDA orphan drug designation for its lead oncolytic virus candidate, MVdeltaC to treat pleural ...
Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, announced that the US Food and Drug Administration has granted orphan drug designation (ODD) to its lead investigational therapy, MVdeltaC, for the …